News

Key TakeawaysTransthyretin amyloid cardiomyopathy (ATTR-CM) is a type of heart disease caused by abnormal protein buildup in the heart, but its symptoms often look…

Rare diseases tend to remain under-discussed, underfunded, and underdiagnosed. One such condition is Amyloidosis, a collection of rare and potentially fatal…

– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –– In four out of five pending patients,…

AbstractTransthyretin amyloidosis (ATTR) with heart involvement is a progressive, life-threatening condition characterized by amyloid fibril deposition in the…

Carbon-11 Pittsburgh compound B (C-11 PiB) PET/CT demonstrates robust capability for detecting cardiac amyloidosis and accurately differentiating its subtypes,…

A Donegal man who was one of the first ever patients on an Amyloidosis treatment trial says the therapy has transformed his health.James Green, an accountant from…

Dr. Sami Khella, Professor of Neurology and co-founder of the Amyloidosis Program at the University of Pennsylvania discussed the latest in diagnosis, treatment,…

This webinar “Coffee Chat” style webinar is your chance to learn about the different programs and projects ARC has been working on in 2025! Hear directly from ARC…

Clinical Takeaway: Two studies show that cardiac amyloidosis is more common than we thought.ContextCardiac amyloidosis is traditionally considered to be relatively…

At Porterhouse, we are proud to support World Amyloidosis Day.  Our article shines a light on this rare condition to help drive greater understanding, improve…